Literature DB >> 17991366

[Etiological profile of urinary tract infections and antimicrobial susceptibility of urinary pathogens].

J M Eiros Bouza1, C Ochoa Sangrador.   

Abstract

A review on the etiological profile of urinary tract infections in childhood and the sensitivity pattern of urinary pathogens in Spain is presented. Escherichia coli continues to be the main etiological agent of urinary tract infection in childhood. Consequently, its sensitivity pattern will usually determine the choice of empirical therapy. The predominance of E. coli is reduced in certain circumstances, in which the presence of other microorganisms is increased. However, the clinical information available at diagnosis does not allow accurate identification of the etiology; only staining and microscopic urine examination can help in treatment selection. In Spain, E. coli presents a high percentage of resistance to ampicillin and cotrimoxazole, whereas second- and third-generation cephalosporins, fosfomycin, aminoglycosides and amoxicillin-clavulanate maintain high sensitivity. In some areas, amoxicillin-clavulanate and first-generation cephalosporins show high levels of resistance, which can limit their empirical use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991366     DOI: 10.1016/s1695-4033(07)70713-0

Source DB:  PubMed          Journal:  An Pediatr (Barc)        ISSN: 1695-4033            Impact factor:   1.500


  2 in total

1.  Changes in bacterial resistance patterns in children with urinary tract infections on antimicrobial prophylaxis at University Hospital in Split.

Authors:  Tanja Ilić; Sanda Gračan; Adela Arapović; Vesna Capkun; Mirna Subat-Dežulović; Marijan Saraga
Journal:  Med Sci Monit       Date:  2011-07

2.  Etiological and Resistance Profile of Bacteria Involved in Urinary Tract Infections in Young Children.

Authors:  Antonio Sorlózano-Puerto; José María Gómez-Luque; Juan de Dios Luna-Del-Castillo; José María Navarro-Marí; José Gutiérrez-Fernández
Journal:  Biomed Res Int       Date:  2017-04-11       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.